RxDoctor Payments Data

Joshua Roark, MD

Interventional Cardiology · Portland, ORNPI 1619389368

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (58.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Medtronic at 32.9% of the total. Reporting peaked in 2023 at $5,438 and has fallen 90.6% since, to $513 in 2025.

$15,769in general payments, 2019–2025

Across 141 payments — averaging $111.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abiomed$4K
  • Abbott$3K
  • CSL Behring$2K
  • Angiodynamics, Inc.$261
  • Shockwave Medical, Inc$180
  • plus $591 from 8 others

What the payments were for

  • Travel & lodging$9,22659%
  • Food & beverage$6,33240%
  • Education$2111%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,769 in reported general payments places this provider in the 70th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon

Medicare billing

Part B allowed, 2024
$88,333
Medicare patients
314
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$140,588
EntrestoSacubitril/Valsartan40$50,791
JardianceEmpagliflozin18$21,214
Repatha SureclickEvolocumab13$8,558
Ranolazine ErRanolazine44$4,476
Metoprolol Succinate253$3,551
Atorvastatin Calcium141$1,626
ClopidogrelClopidogrel Bisulfate117$1,450
Isosorbide Mononitrate ErIsosorbide Mononitrate88$1,350
Amiodarone Hcl36$1,098
Losartan Potassium104$1,054
Rosuvastatin Calcium64$705
Carvedilol76$616
Ezetimibe21$541
Amlodipine Besylate66$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$159$140,588101 claims
Boehringer IngelheimJardiance$11$21,21418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 interventional cardiology providers in Oregon.

Other interventional cardiology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →